Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLiu ZixianMGMing Gong

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals rituximab and doxorubicin improve progression-free survival in non-Hodgkin's lymphoma patients, suggesting effective therapeutic approaches.

Key Points

  • Observed complete metabolic response in patients treated with rituximab and doxorubicin, highlighting the effectiveness of innovative approaches.
  • The use of PET-CT imaging enabled accurate assessment of metabolic response, identifying treatment efficacy.
  • Clinical data from 22 patients showed an overall response rate of 86.3% to first-line therapies, emphasizing the need for optimal treatment strategies.
  • Results indicate potential benefits of additional therapies like prednisone in enhancing progression-free survival for this cohort.

Cite This Study

Zixian et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e283https://doi.org/10.1182/blood-2025-7201
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025
  2. 2Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China2025
  3. 3Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization2025
  4. 4A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  5. 5Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study2025